About Us

4PHASES AS, based in Oslo, Norway owns the CALITAV3.0 Web-based real-time software, which consists of 23 integrated modules covering all functions needed from producer to patient in clinical trials.

CALITA V3.0 is a game-changing and unique product in the marketplace today.
This software was originally developed by Life Science Applications, IBM, AstraZeneca, LAB France, Yamanlouchi& Calita, and was bought by 4Phases AS in November 2016.

Development time for new medications today is a minimum of 13 years. Patent protection of a medication only lasts 20 years, beginning from the time of invention, not from the time it makes it to the market. This leaves a very small window of profit realization before the patent runs out. Users of CALITA V3.0 are expected to cut development time by more than 3 years and bring new medications to market with many more years of profit realization.

Currently studies are planned to recruit 10 —15% more patients than needed for reaching the statistical endpoint.

Our customers might reduce planned recruit to 5%.

Better collaboration between study team members and investigators.

Improved integration between IT systems, to many silos (e.g. use of Excel).

Imaging transfer from sites to the Image Review Center can be streamlined (time it takes from patient inclusion to image data arriving at the IRC).

Improving capabilities for ongoing QC and medical review of images prior to independent read.

Data collection of independent reads (e.g. through electronic data capture of independent read data).

Enabling «distributed independent reads» regardless of location.

Technology support of the infrastructure.

Control of study payments, progress, schedule, finance. Lead time before able to present total study progress.

Retrieval for re-analysis with new segmentation protocols, new volumetric, etc.

Currently studies are planned to recruit 10 —15% more patients than needed for reaching the statistical endpoint.